

1. Zhao W, Robbins ME. Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. *Curr Med Chem* 2009;16:130–143.
2. Fleckenstein K, Zgonjanin L, Chen L, et al. Temporal onset of hypoxia and oxidative stress after pulmonary irradiation. *Int J Radiat Oncol Biol Phys* 2007;68:196–204.
3. Rube CE, Wilfert F, Palm J, et al. Irradiation induces a biphasic expression of pro-inflammatory cytokines in the lung. *Strahlenther Onkol* 2004;180:442–448.
4. Crestani B, Valeyre D, Roden S, et al. Bronchiolitis obliterans organizing pneumonia syndrome primed by radiation therapy to the breast. The Groupe d'Etudes de Recherche sur les Maladies Orphelines Pulmonaires (GERM"O" P) *Am J Respir Crit Care Med* 1998;158:1929–1935.
5. Vujaskovic Z, Anscher MS, Feng QF, et al. Radiation-induced hypoxia may perpetuate late normal tissue injury. *Int J Radiat Oncol Biol Phys* 2001;50:851–855.
6. Monson JM, Stark P, Reilly JJ, et al. Clinical radiation pneumonitis and radiographic changes after thoracic radiation therapy for lung carcinoma. *Cancer* 1998;82:842–850.
7. Robnett TJ, Machtay M, Vines EF, et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. *Int J Radiat Oncol Biol Phys* 2000;48:89–94.
8. Movsas B, Raffin TA, Epstein AH, et al. Pulmonary radiation injury. *Chest* 1997;111:1061–1076.
9. Taghian AG, Assaad Si, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. *J Natl Cancer Inst* 2001;93:1806–1811.
10. Catane R, Schwade JG, Turrisi AT 3rd, et al. Pulmonary toxicity after radiation and bleomycin: a review. *Int J Radiat Oncol Biol Phys* 1979;5:1513–1518.
11. Dehing-Oberije C, De Ruyscher D, van Baardwijk A, et al. The importance of patient characteristics for the prediction of radiation-induced lung toxicity. *Radiother Oncol* 2009;91:421–426.
12. Bachaud JM, Marre D, Dugai I, et al. The impact of 18F-fluorodeoxyglucose positron emission tomography on the 3D conformal radiotherapy planning in patients with non-small cell lung cancer. *Cancer Radiother* 2005;9:602–609.
13. Ciernik IF, Dizendorf E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. *Int J Radiat Oncol Biol Phys* 2003;57:853–863.
14. Goldberg SN, Gazelle GS, Compton CC, et al. Radiofrequency tissue ablation in the rabbit lung: efficacy and complications. *Acad Radiol* 1995;2:776–784.
15. Gandhi NS, Dupuy DE. Image-guided radiofrequency ablation as a new treatment option for patients with lung cancer. *Semin Roentgenol* 2005;40:171–181.
16. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. *JAMA* 2010;303:1070–1076.
17. Fakiris AJ, McGarry RC, Yiannoutsos CT, et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study. *Int J Radiat Oncol Biol Phys* 2009;75:677–682.
18. McDonald S, Rubin P, Phillips TL, et al. Injury to the lung from cancer therapy: clinical syndromes, measurable endpoints, and potential scoring systems. *Int J Radiat Oncol Biol Phys* 1995;31:1187–1203.
19. Herishanu Y, Pollack A, Leider-Trejo L, et al. Fatal interstitial pneumonitis related to rituximab-containing regimen. *Clin Lymphoma Myeloma* 2006;6:407–409.
20. Poust JC, Woolery JE, Green MR. Management of toxicities associated with high-dose interleukin-2 and biochemotherapy. *Anticancer Drugs* 2013;24:1–13.
21. Marks LB. Physiology-based studies of radiation-induced normal tissue injury. *Radiother Oncol* 1999;51:101–103.
22. Theuvs JC, Muller SH, Seppenwoolde Y, et al. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: A follow-up study. *J Clin Oncol* 1999;17:3091–3100.
23. Myers JN, O'neil KM, Walsh TE, et al. The pulmonary status of patients with limited-stage small cell lung cancer 15 years after treatment with chemotherapy and chest irradiation. *Chest* 2005;128:3261–3268.
24. Araya J, Maruyama M, Sassa K, et al. Ionizing radiation enhances matrix metalloproteinase-2 production in human lung epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 2001;280:L30–L38.
25. Novakova-Jiresova A, Van Gamen MM, Coppes RP, et al. Transforming growth factor-beta plasma dynamics and post-irradiation lung injury in lung cancer patients. *Radiother Oncol* 2004;71:183–189.
26. Zhao L, Wang L, Ji W, et al. Elevation of plasma TGF-beta1 during radiation therapy predicts radiation-induced lung toxicity in patients with non-small-cell lung cancer: a combined analysis from Beijing and Michigan. *Int J Radiat Oncol Biol Phys* 2009;74:1385–1390.
27. Madani I, De Ruyck K, Goeminne H, et al. Predicting risk of radiation-induced lung injury. *J Thorac Oncol* 2007;2:864–874.
28. Chen Y, Rubin P, Williams J, et al. Circulating IL-6 as a predictor of radiation pneumonitis. *Int J Radiat Oncol Biol Phys* 2001;49:641–648.
29. Goto K, Kodama T, Sekine I, et al. Serum levels of KL-6 are useful biomarkers for severe radiation pneumonitis. *Lung Cancer* 2001;34:141–148.
30. Bai L, Zhao J, Yu H, et al. The CD36 dynamic change after radiation therapy in lung cancer patients and its correlation with symptomatic radiation pneumonitis. *Radiother Oncol* 2013;107:389–391.
31. Severin DM, Leong T, Cassidy B, et al. Novel DNA sequence variants in the hHR23 DNA repair gene in radiosensitive cancer patients. *Int J Radiat Oncol Biol Phys* 2001;50:1323–1331.
32. Andreassen CN, Alsner K, Overgaard M, et al. Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. *Radiother Oncol* 2003;69:127–135.
33. Andreassen CN, Alsner J, Overgaard J, et al. TGFBI polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. *Radiother Oncol* 2005;75:18–21.
34. Vahid B, Mehrotra A. Trastuzumab (Herceptin)-associated lung injury. *Respirology* 2006;11:655–658.
35. Medhora M, Gao F, Jacobs ER, et al. Radiation damage to the lung: mitigation by angiotensin-converting enzyme (ACE) inhibitors. *Respirology* 2012;17:66–71.
36. Movsas B, Scott C, Langer C, et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01. *J Clin Oncol* 2005;23:2145–2154.
37. Graves PR, Siddiqui F, Anscher MS, et al. Radiation pulmonary toxicity: from mechanisms to management. *Semin Radiat Oncol* 2010;20:201–207.
38. Crilley P, Topolsky D, Styler MJ, et al. Extramedullary toxicity of a conditioning regimen containing busulfan, cyclophosphamide and etoposide in 84 patients undergoing autologous and allogeneic bone marrow transplantation. *Bone Marrow Transplant* 1995;15:361–365.
39. Ghalié R, Reynolds J, Valentino LA, et al. Busulfan-containing pre-transplant regimens for the treatment of solid tumors. *Bone Marrow Transplant* 1994;14:437–442.
40. Malik SE, Myers JL, DeRemee RA, et al. Lung toxicity associated with cyclophosphamide. Two distinct patterns. *Am J Respir Crit Care Med* 1996;154:1851–1856.
41. Cooper JA Jr, White DA, Matthay RA. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. *Am Rev Respir Dis* 1986;133:321–340.
42. Pulmonary toxicity associated with systemic antineoplastic therapy. Uptodate. <http://www.uptodate.com>. Accessed September 2010.
43. Khong AT, McCarthy J. Chlorambucil induced pulmonary disease: a case report and review of the literature. *Am Hematol* 1998;77:85–87.
44. Goucher C, Rowland V, Hawkins J. Melphalan-induced pulmonary interstitial fibrosis. *Chest* 1980;77:805–806.
45. Herman EH, Hasinoff BB, Zhang J, et al. Morphologic and morphometric evaluation of the effect of ICRF-187 on bleomycin-induced pulmonary toxicity. *Toxicology* 1995;98:163–175.
46. Freeman BA, Crapo JD. Biology of disease: free radicals and tissue injury. *Lab Invest* 1982;47:412–426.
47. Lewis RA, Austen KF. The biologically active leukotrienes. Biosynthesis, metabolism, receptors, functions, and pharmacology. *J Clin Invest* 1984;73:889–897.
48. Waid-Jones MI, Coursin DB. Perioperative considerations for patients treated with bleomycin. *Chest* 1991;99:993–999.
49. Gilson AJ, Sahn SA. Reactivation of bleomycin lung toxicity following oxygen administration. A second response to corticosteroids. *Chest* 1985;88:304–306.
50. Khalil N, Whitman C, Zuo L, et al. Regulation of alveolar macrophage transforming growth factor-beta secretion by corticosteroids in bleomycin-induced pulmonary inflammation in the rat. *J Clin Invest* 1993;92:1812–1818.
51. Chandler DB. Possible mechanisms of bleomycin-induced fibrosis. *Clin Chest Med* 1990;11:21–30.
52. King SL, Lichtler AC, Rowe DW, et al. Bleomycin stimulates pro-alpha 1 (I) collagen promoter through transforming growth factor beta response element by intracellular and extracellular signaling. *J Biol Chem* 1994;269:13156–13161.
53. Veerappan A, O'Connor NJ, Brazin J, et al. Mast cells: a pivotal role in pulmonary fibrosis. *DNA Cell Biol* 2013;32:206–218.
54. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. *Clin Chest Med* 1990;11:1–20.
55. Ferrando AA, Pendas AM, Llano E, et al. Gene characterization, promoter analysis, and chromosomal localization of human bleomycin hydrolase. *J Biol Chem* 1997;272:33298–33304.
56. Nuver J, Lutke Holzik MF, van Zweeken M, et al. Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. *Pharmacogenet Genomics* 2005;15:399–405.
57. Haston CK, Wang M, Dejourne RE, et al. Bleomycin hydrolase and a genetic locus within the MHC affect risk for pulmonary fibrosis in mice. *Hum Mol Genet* 2002;11:1855–1863.
58. Paun A, Lemay AM, Tomko TC, et al. Association analysis reveals genetic variation altering bleomycin-induced pulmonary fibrosis in mice. *Am J Respir Cell Mol Biol* 2013;48:330–336.
59. Stefanov AN, Fox J, Haston CK. Positional cloning reveals strain-dependent expression of Trim16 to alter susceptibility to bleomycin-induced pulmonary fibrosis in mice. *PLoS Genet* 2013;9:e1003203.
60. Barnett GC, Coles CE, Elliott RM, et al. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study. *Lancet Oncol* 2012;13:65–77.
61. Rivera MP, Kris MG, Gralla RJ, et al. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. *Am J Clin Oncol* 1995;18:245–250.
62. Linette DC, McGee KH, McFarland JA. Mitomycin induced pulmonary toxicity: case report and review of the literature. *Ann Pharmacol Ther* 1992;26:481–484.

63. White DA, Gellene RA, Gupta S, et al. Pulmonary cell populations in the immunosuppressed patient. Bronchoalveolar lavage findings during episodes of pneumonitis. *Chest* 1985;88:352–359.
64. Imokawa S, Colby TV, Leslie KO, et al. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. *Eur Respir J* 2000;15:373–381.
65. Haupt HM, Hutchins GM, Moore GW. Ara-C lung: noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia. *Am J Med* 1981;70:256–261.
66. Gupta N, Ahmed I, Steinberg H, et al. Gemcitabine-induced pulmonary toxicity case report and review of the literature. *Am J Clin Oncol* 2002;25:96–100.
67. Esteban E, Villanueva N, Muniz I, et al. Pulmonary toxicity in patients treated with gemcitabine plus vinorelbine or docetaxel for advanced non-small cell lung cancer: outcome data on a randomized phase II study. *Invest New Drugs* 2008;26:67–74.
68. Kouroussis C, Mavroudis D, Kakolyris S, et al. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study. *Lung Cancer* 2004;44:363–368.
69. Helman DL Jr, Byrd JC, Alex NC, et al. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes. *Chest* 2002;122:785–790.
70. Weiss RB, Donehower RC, Wiernik PH, et al. Hypersensitivity reactions from Taxol. *J Clin Oncol* 1990;8:1263–1268.
71. Ramanathan RK, Reddy VV, Holbert JM, et al. Pulmonary infiltrates following administration of paclitaxel. *Chest* 1996;110:289–292.
72. Ostoros G, Pretz A, Fillinger J, et al. Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. *Int J Gynecol Cancer* 2006;16:391–393.
73. Shepherd GM. Hypersensitivity reactions to chemotherapeutic drugs. *Clin Rev Allergy Immunol* 2003;24:253–262.
74. Suzuki H, Aoshiba K, Yokohori N, et al. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. *Cancer Res* 2003;63:5054–5059.
75. Okamoto I, Fujii K, Matsumoto M, et al. Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. *Lung Cancer* 2003;40:339–342.
76. Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. *Oncologist* 2003;8:303–306.
77. Takano T, Ohe Y, Kusumoto M, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. *Lung Cancer* 2004;45:93–104.
78. Nagaria NC, Cogswell J, Chose JK, et al. Side effects and good effects from new chemotherapeutic agents: case 1. Gefitinib-induced interstitial fibrosis. *J Clin Oncol* 2005;23:2423–2424.
79. Vahid B, Esmaili A. Erlotinib-associated pneumonitis: report of two cases. *Can Respir J* 2007;14:167–170.
80. Lin JT, Yeh KT, Fang HY, et al. Fulminant, but reversible interstitial pneumonitis associated with imatinib mesylate. *Leuk Lymphoma* 2006;47:1693–1695.
81. Grimson P, Goldstein D, Schneeweiss J, et al. Corticosteroid-responsive interstitial pneumonitis related to imatinib mesylate with successful rechallenge, and potential causative mechanisms. *Intern Med J* 2005;35:136–137.
82. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. *Am J Respir Crit Care Med* 2007;176:814–818.
83. Bergeron A, Bergot E, Vilela G, et al. Hypersensitivity pneumonitis related to imatinib mesylate. *J Clin Oncol* 2002;20:4271–4272.
84. Miyakoshi S, Kami M, Yuji K, et al. Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. *Blood* 2006;107:3492–3494.
85. Liotta M, Rose PG, Escobar PF. Pulmonary hypertension in two patients treated with bevacizumab for recurrent ovarian cancer. *Gynecol Oncol* 2009;115:308–309.
86. Champion L, Stern M, Israel-Biet D, et al. Brief communications: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. *Ann Intern Med* 2006;144:505–509.
87. Pham PT, Pham PC, Danovitch GM, et al. Sirolimus-associated pulmonary toxicity. *Transplantation* 2004;77:1215–1220.
88. Chhajed PN, Dickennann M, Bubendorf L, et al. Patterns of pulmonary complications associated with sirolimus. *Respiration* 2006;73:367–374.
89. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. *Eur J Cancer* 2006;42:1875–1880.
90. White DA, Schwartz LH, Dimitrijevic S, et al. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD 001). *J Thor Oncol* 2009;4:1357–1363.
91. White DA, Camus P, Endo M, et al. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. *Am J Respir Crit Care Med* 2010;182:396–403.
92. Amit L, Beh-Aharon I, Vidal L, et al. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors—a meta-analysis and systematic review. *PLoS One* 2013;8:e51780.
93. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. *Clin Lung Cancer* 2009;10:28–35.
94. Liotta M, Rose PG, Escobar PF. Pulmonary hypertension in 2 patients treated with bevacizumab for recurrent ovarian cancer. *Gynecol Oncol* 2009;115:308–309.
95. Charpidou AG, Gkiozos I, Tsimpoukis S, et al. Therapy-induced toxicity of the lungs: an overview. *Anticancer Res* 2009;29:631–639.
96. Barjaktarevic IZ, Qadir N, Suri A, et al. Organizing pneumonia as a side effect of ipilimumab treatment of melanoma. *Chest* 2013;143:858–861.
97. Tissot C, Carsin A, Freymond N, et al. Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy. *Eur Respir J* 2013;41:246–247.
98. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N Engl J Med* 2012;366:2443–2454.
99. Gagnadoux F, Roiron C, Carrie E, et al. Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. *Am J Clin Oncol* 2002;25:388–390.
100. Baker WJ, Fistel SJ, Jones RV, et al. Interstitial pneumonitis associated with ifosfamide therapy. *Cancer* 1990;65:2217–2221.
101. Madarnas Y, Webster P, Shorter AM, et al. Irinotecan-associated pulmonary toxicity. *Anticancer Drugs* 2000;11:709–713.
102. Maitland ML, Wilcox R, Hogarth DK, et al. Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. *Lung Cancer* 2006;54:243–245.
103. Edgerton CC, Gilman M, Roth BJ. Topotecan-induced bronchiolitis. *South Med J* 2004;97:699–701.
104. Onozawa M, Hashino S, Sogabe S, et al. Side effects and good effects from new chemotherapeutic agents. Case 2. Thalidomide-induced interstitial pneumonitis. *J Clin Oncol* 2005;23:2425–2426.
105. Sakanashi Y, Takeya M, Yoshimura T, et al. Kinetics of macrophage subpopulations and expression of monocyte chemoattractant protein-1 (MCP-1) in bleomycin-induced lung injury of rats studied by a novel monoclonal antibody against rat MCP-1. *J Leukoc Biol* 1994;56:741–750.
106. White DA, Rankin JA, Stover DE, et al. Methotrexate pneumonitis. Bronchoalveolar lavage findings suggest an immunologic disorder. *Am Rev Respir Dis* 1989;139:18–21.
107. White DA, Kris MG, Stover DE. Bronchoalveolar lavage cell populations in bleomycin lung toxicity. *Thorax* 1987;42:551–552.
108. Azoulay E, Herigault S, Levame M, et al. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. *Crit Care Med* 2003;31:1442–1448.
109. Baluna R, Vitetta ES. Vascular leak syndrome: a side effect of immunotherapy. *Immunopharmacology* 1997;37:117–132.
110. Harada C, Kawaguchi T, Ogata-Suetsugu S, et al. EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium. *Am J Respir Crit Care Med* 2011;183:743–751.
111. Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. *Drug Saf* 2013;36:413–426.
112. Morelon E, Stern M, Israel-Biet D, et al. Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients. *Transplantation* 2001;72:787–790.
113. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. *Eur J Cancer* 2006;42:1875–1880.
114. Kang W, Kim JS, Cho SH, et al. Nonspecific interstitial pneumonitis after bortezomib and thalidomide treatment in a multiple myeloma patient. *Yonsei Med J* 2010;51:448–450.
115. Kang MH, Ju JH, Kim HG, et al. Thalidomide induced nonspecific interstitial pneumonia in patient with relapsed multiple myeloma. *Korean J Intern Med* 2010;25:447–449.
116. Kilickap S, Abali H, Celik I. Bevacizumab, bleeding, thrombosis, and warfarin. *J Clin Oncol* 2003;21:3542; author reply 3543.
117. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. *Am J Physiol Cell Physiol* 2001;280:C1375–C1386.
118. Lei KI, Leung WT, Johnson PJ. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma. *Br J Cancer* 1994;70:1009–1013.
119. Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid. *Blood* 1994;84:3843–3849.
120. Rossi SE, Erasmus JJ, McAdams HP, et al. Pulmonary drug toxicity: radiologic and pathologic manifestations. *Radiographics* 2000;20:1245–1259.
121. Wolkowicz J, Sturgeon J, Pawji M, et al. Bleomycin-induced pulmonary function abnormalities. *Chest* 1992;101:97–101.
122. Ohnishi H, Yokoyama A, Yasuhara Y, et al. Circulating KL-6 levels in patients with drug induced pneumonitis. *Thorax* 2003;58:872–875.
123. Kobayashi J, Kitamura S. KL-6: a serum marker for interstitial pneumonia. *Chest* 1995;108:311–315.
124. Ancher MS, Peters WP, Reisenbichler H, et al. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. *N Engl J Med* 1993;328:1592–1598.
125. Schuller-Levis G, Gordon RE, Wang C, et al. Protection of bleomycin-induced fibrosis and inflammation by taurine. *Int Immunopharmacol* 2009;9:971–977.
126. Grossman RF, Frost A, Zamel N, et al. Results of single-lung transplantation for bilateral pulmonary fibrosis. The Toronto Lung Transplant Group. *N Engl J Med* 1990;322:727–733.